Propranolol for a treatment of lymphatic malformatio
Phase 2
- Conditions
- lymphatic malformation
- Registration Number
- JPRN-UMIN000008498
- Lead Sponsor
- niversity of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Heart disease 2) Hypotension (Systolic blood pressure < 70mmHg) 3) Bradycardia (Pulse rate <60/min) 4) Asthma 5) Diabetic ketoacidosis,metabolic acidosis 6)idiopathic hypoglycemia,uncontroled diabetes (Blood suger < 60mg/dl) 7)fasted state over one month 8)peripheral circulatory disturbance 9)untreated phenochromocytoma 10)administration of thioridazine 11)administration of rizatriptan benzoate 12)oral use of antihypertensive agent 13)oral use or local injection of adrenal cortical steroid 14)Patient who was considered ineligible by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method bleeding and pain
- Secondary Outcome Measures
Name Time Method (Reduction ratio) Measured by MRI and echo images of lymphatic malformation (Other) Changes in the lymphoid follicles (Safety endpoints) Bradycardia, hypotension, drowsiness, insomnia, rash, diarrhea, difficulty breathing, wheezing, decreased blood glucose